Collagenous colitis with rapid response to sulphasalazine

T. Rokkas,1 M.I. Filipe2 and G.E. Sladen1

1Gastroenterology Unit, Division of Medicine and 2Department of Histopathology, UMDS Guy's and St Thomas' Hospitals, Guy's Hospital, London SE1 9RT, UK.

Summary: A case of collagenous colitis in a young female with a rapid response to sulphasalazine both symptomatically and histologically is reported. This is only the third such response to be reported. In most published accounts, collagenous colitis fails to respond to treatment and runs a very prolonged course.

Introduction

In 1976 Lindstrom1 reported the first case of a previously unrecognized entity which was characterized by the association of chronic, watery diarrhoea, and a marked deposition of collagen below the surface epithelium. He introduced the term 'collagenous colitis' for this unusual disease and since then approximately 30 cases have been described, mainly from Europe.2–12 The aetiology is unknown and no specific treatment is so far available.8 Most reported cases have been given sulphasalazine but have failed to respond9 unlike 'microscopic colitis' which usually does respond.

We present a case of collagenous colitis with an impressive rapid symptomatic response to sulphasalazine and complete histological resolution of the collagen deposits which continued throughout the year's follow up.

Case report

A 33 year old white female patient was seen in November 1985 with a one year history of profuse watery diarrhoea (up to 20 stools/day) and intermittent colicky abdominal pain. She described the stools as frothy, without blood or mucus and not usually offensive. Otherwise her general health had been good until 1 month before her attendance when she started to lose weight (7 kg over 1 month) and felt tired. Anti-diarrhoeal drugs were ineffective. Physical examination was unremarkable except that the abdomen was a little distended and noisy. Sigmoidoscopy revealed markedly watery stools with rather oedematous but otherwise unremarkable mucosa. Rectal biopsy showed debasement of the surface epithelium with complete loss of goblet cells and infiltration by neutrophils. There was a thick irregular layer of collagen varying from 7 to 25 μm that had replaced the normal basement membrane (Figure 1). It had a very coarsely fibrillar structure with its interstices lightly infiltrated by eosinophils, neutrophils, lymphocytes and macrophages in small numbers. No amyloid was demonstrated in a Congo red preparation. Faecal cultures on several occasions were negative for pathogens during the few months before diagnosis. Haemoglobin, blood film, erythrocyte sedimentation rate and blood chemistry were normal. Barium enema and barium meal with follow through were also normal. The patient was treated with oral sulphasalazine 3 g/day and within a few days her diarrhoea and abdominal pain began to improve. By the end of one week she was completely free of symptoms and her bowel habit was normal (1–3 formed stools daily). Sulphasalazine was discontinued one month after the start of treatment without relapse. Six months after the initial presentation a rectal biopsy showed complete disappearance of the collagen layer and the mucosa appeared normal (Figure 2). One year after her initial presentation the patient remained free of symptoms and multiple rectal and colonic biopsies obtained by flexible sigmoidoscopy showed no evidence of the collagen layer or inflammation.

Discussion

The case we described has all the characteristics of collagenous colitis. The patient was female and it is
known that the disease is much more common in women, although the reason for this is unknown. She presented with profuse watery diarrhoea and intermittent colicky abdominal pain which are the main clinical characteristics of the disease. Her first rectal biopsy showed a subepithelial collagen layer of 7 to 25μm in thickness which was well above the range of 0.4–4.6μm observed by Van den Oord et al. in 564 rectal biopsies from normal subjects (200), patients with inflammatory bowel disease (104) and patients with miscellaneous colonic disorders (260).

The aetiology of collagenous colitis is unknown but the most widespread hypothesis is that collagen accumulation results from increased synthesis and/or decreased cell turnover. When the cell turnover is decreased, fibrocytes remain longer in the mature phase and so produce more collagen. It is known that in the immature replicative phase fibroblasts produce very little collagen and in the colon it is only after they have moved to the crypt together with the epithelial cells that they are able to synthesize collagen. The possibility that an infectious factor is responsible has also been postulated by others who reported remission of one patient's symptoms and a reduction of collagen layer thickness after a course of mepacrine, a drug which is generally used as an antimicrobial agent.

So far there has been a widespread belief that there was no effective treatment for this disease. However, there are two reported cases with
symptomatic and histological response to sulphasalazine and in one sulphasalazine was given with local steroid therapy. Our patient responded impressively to sulphasalazine both clinically within the first week of treatment and histologically as proved by normal rectal and colonic histology at 6 and 12 months. The mechanism by which this treatment leads to dissolution of the collagen layer is not clear. Furthermore it is obscure which of the two constituents of sulphasalazine, i.e. sulphapyridine (antimicrobial agent) or salicylate (anti-inflammatory agent), is responsible for this histological regression. In any case this regression suggests that the disease is not inevitably progressive and that sulphasalazine should prove to be effective treatment at least in some patients.

References

Collagenous colitis with rapid response to sulphasalazine.

T. Rokkas, M. I. Filipe and G. E. Sladen

Postgrad Med J 1988 64: 74-76
doi: 10.1136/pgmj.64.747.74

Updated information and services can be found at:
http://pmj.bmj.com/content/64/747/74

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/